drugset
drugset / Trial / NCT07618247

Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants

NCT07618247 ↗

Phase 1 Not yet recruiting 64 enrolled Iongen Therapeutics Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001119 in Healthy Participants

Timeline

Start
2026-06-04
Primary completion
2027-04-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IG001119 Unknown — Oral

Indications

No indication recorded.